NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00976911,AURELIA: A Study of Avastin (Bevacizumab) Added to Chemotherapy in Patients With Platinum-resistant Ovarian Cancer,https://clinicaltrials.gov/study/NCT00976911,,COMPLETED,"This randomized, open-label, 2-arm study will evaluate the efficacy and safety of Avastin added to chemotherapy versus chemotherapy alone in patients with epithelial ovarian, fallopian tube or primary peritoneal cancer with disease progression within 6 months of platinum therapy. All patients will receive standard chemotherapy with either paclitaxel or topotecan or liposomal doxorubicin. Patients randomized to Arm 2 of the study will receive Avastin (10 mg/kg iv 2-weekly or 15 mg/kg iv 3-weekly) concomitantly. Anticipated time on study treatment is until disease progression. Patients will then receive standard of care, those in Arm 1 (chemotherapy only) may opt to receive Avastin (15 mg/kg iv 3-weekly). Target sample size is 100-500 individuals.",YES,Ovarian Cancer,DRUG: Bevacizumab|DRUG: liposomal doxorubicin|DRUG: paclitaxel|DRUG: topotecan,"Percentage of Participants With Disease Progression or Death (Data Cutoff 14 November 2011), Progression free survival was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurs first. Progression was based on tumour assessment made by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) criteria (for participants with measurable disease), and for those with non-measurable disease presence or absence of lesions was noted., Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 14 November 2011|Progression Free Survival (PFS; Data Cutoff 14 November 2011), PFS was defined as the time from the date of randomization to the first documented disease progression or death, whichever occurred first. Progression was based on tumor assessment made by the investigators according to the RECIST criteria (for participants with measurable disease), and for those with non-measurable disease presence or absence of lesions was noted. Time from randomization to occurrence of disease progression or death was measured in months. An event was defined as the earliest progressive disease or death that occurred on or before the cutoff date (14 November 2011), regardless of start of nonprotocol specified anti-cancer therapy or the bevacizumab monotherapy. Disease progression was assessed by investigator according to RECIST or by symptom deterioration, and could not be declared on the basis of rising cancer antigen 125 (CA125) levels alone. Kaplan-Meier methodology was used. 95% CI for median was computed using the method of Brookmeyer and Crowley., Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 14 November 2011","Percentage of Participants With Best Overall Confirmed Objective Response of Complete Response (CR) or Partial Response (PR) Per Modified RECIST (Data Cutoff 14 November 2011), Objective Response was determined by the investigator using modified RECIST criteria, Version 1.0. An objective response was a complete or partial overall confirmed response as determined by investigators. CR defined as complete disappearance of all target and non-target lesions and no new lesions. PR defined as greater than or equal to (≥) 30 percent (%) decrease in the sum of appropriate diameters of all target measurable lesions, no progress in the non-measurable disease, and no new lesions. 95% CI computed using the normal approximation to the binomial distribution., Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 14 November 2011|Duration of Objective Response (Data Cutoff 14 November 2011), For randomized participants who achieved an objective response per modified RECIST, duration of objective response was defined as the time from the date of the first occurrence of a CR or PR (whichever occurred first) until the date that progressive disease or death was documented (whichever occurred first). Participants who had an objective response and did not experience disease progression or death by the time of analysis were censored at the time of the last tumor assessment. Summaries of duration of objective response (median and percentiles) were estimated from Kaplan-Meier curves. 95% CI for duration of objective response was computed using the method of Brookmeyer and Crowley., Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 14 November 2011|Percentage of Participants Who Died (Data Cutoff 25 January 2013), Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 25 January 2013|Overall Survival (Data Cutoff 25 January 2013), Duration of overall survival was defined as the time from randomization to death of any cause. Kaplan-Meier methodology was used. The OS data for participants for whom no death was captured in the clinical database were censored at the last time they were known to be alive. 95% CI was computed using the method of Brookmeyer and Crowley., Screening Visit, Every 8 weeks (or 9 weeks if receiving topotecan) until progression reported between day of first participant randomized (29 October 2009) until cutoff date of 25 January 2013|European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Ovarian (OV) 28 Abdominal/Gastrointestinal (AB/GI) Symptom Scale - Percentage of Responders (Data Cutoff 14 November 2011), The EORTC OV-28 module is a questionnaire that focuses on issues specific to ovarian cancer. It assesses AB/GI symptoms, among others. Participants were asked to indicate the extent to which they experienced AB/GI symptoms in the week prior to assessment. Participants responded on a scale of 1-4 (1=not at all, 2=a little, 3=quite a bit, 4=very much) to the following: Did you have abdominal pain? Did you have a bloated feeling in your abdomen/stomach? Did you have problems with your clothes feeling too tight? Did you experience any change in bowel habit as a result of your disease or treatment? Were you troubled by passing wind/gas/flatulence? Have you felt full too quickly after beginning to eat? Have you had indigestion/heartburn? Data are transformed to a scale from 0 to 100. Lower scores represent better health (fewer symptoms). Participants were considered a responder if they had a 10 point or more reduction in EORTC QLQ-OV28 AB/GI symptom scale score from baseline., Baseline and Weeks 8, 9, 16, 18, 24 and 30 (Data Cutoff 14 November 2011)",,Hoffmann-La Roche,,FEMALE,"ADULT, OLDER_ADULT",PHASE3,361,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,MO22224|2009-011400-33,2009-10-29,2014-07-09,2014-07-09,2009-09-15,2015-02-25,2022-06-21,"Institut Jules Bordet, Bruxelles, 1000, Belgium|UZ Antwerpen, Edegem, 2650, Belgium|UZ Leuven Gasthuisberg, Leuven, 3000, Belgium|Clinique Ste-Elisabeth, Namur, 5000, Belgium|University Clinical Centre of the Republic of Srpska, Banja Luka, 78000, Bosnia and Herzegovina|Clinic of Oncology, University Clinical Center Sarajevo, Sarajevo, 7100, Bosnia and Herzegovina|University Clinical Center Tuzla; Clinic for Gynecology and Obstetrition, Tuzla, 75000, Bosnia and Herzegovina|Herlev Hospital; Afdeling for Kræftbehandling, Herlev, 2730, Denmark|Regionshospitalet Herning; Onkologisk afdeling, Herning, 7400, Denmark|Rigshospitalet; Onkologisk Klinik, København Ø, 2100, Denmark|Odense Universitetshospital, Onkologisk Afdeling R, Odense C, 5000, Denmark|Kuopio University Hospital, Kuopio, 70211, Finland|Oulu University Hospital; Gynaecology & Obstetrics Dept, Oulu, 90220, Finland|Clinique Sainte Catherine; Hopital De Semaine, Avignon, 84918, France|Clinique Tivoli; Sce Radiotherapie, Bordeaux, 33000, France|Institut Bergonie; Gynecologie, Bordeaux, 33076, France|Polyclinique Bordeaux Nord Aquitaine; Chimiotherapie Radiotherapie, Bordeaux, 33077, France|Ch De Brive La Gaillarde; Radiotherapie Oncologie, Brive La Gaillarde, 19312, France|Centre Francois Baclesse; Urologie Gynecologie, Caen, 14076, France|Centre Jean Perrin; Hopital De Jour, Clermont Ferrand, 63011, France|Hopital Louis Pasteur; Medecine B, Colmar, 68024, France|Institut Daniel Hollard; Chimiotherapie Ambulatoire, Grenoble, 38000, France|Centre Hospitalier Departemental Les Oudairies, La Roche Sur Yon, 85925, France|Hopital La Source; Onco Med Hematologie Clinique, La Source, 45100, France|Hopital Andre Mignot; Hematologie - Oncologie, Le Chesnay, 78157, France|Centre Jean Bernard, Le Mans, 72015, France|Centre Oscar Lambret; Cancerologie Gynecologique, Lille, 59020, France|Clin Mut De Lyon Eugene Andre; Medecine 3 A, Lyon, 69424, France|Hopital Layne; Medecine Ambulatoire, Mont-de-marsan, 40024, France|Centre Val Aurelle Paul Lamarque; Medecine A1 A2, Montpellier, 34298, France|Polyclinique Gentilly; CHIMIOTHERAPIE AMBULATOIRE, Nancy, 54100, France|Centre Catherine de Sienne; Chimiotherapie, Nantes, 44202, France|Centre Antoine Lacassagne; Hopital De Jour A2, Nice, 06189, France|Polyclinique Kenval ; Radiotherapie Oncologie, Nimes, 30900, France|Hotel Dieu; Hematologie- Oncologie, Paris, 75181, France|Institut Curie; Oncologie Medicale, Paris, 75231, France|Hopital Saint Louis ; Service d Oncologie Medicale Fougere 6 (Pr Misset), Paris, 75475, France|HOPITAL TENON; Cancerologie Medicale, Paris, 75970, France|Clinique Francheville; Radiotherapie, Perigueux, 24000, France|Institut Jean Godinot; Oncologie Medicale, Reims CEDEX, 51056, France|Centre Henri Becquerel; Oncologie Medicale, Rouen, 76038, France|Clinique Armoricaine Radiologie; Cons Externes, Saint Brieuc, 22015, France|Ico Rene Gauducheau; Oncologie, Saint Herblain, 44805, France|Centre Radiotherapie Etienne Dolet, Saint Nazaire, 44600, France|Centre Rene Huguenin; Medecine B, St Cloud, 92210, France|Hopital Civil; Expl Fonct Systeme Nerveux, Strasbourg, 67091, France|Hopitaux Du Leman Site Thonon; Maternite Gynecologie, Thonon Les Bains, 74203, France|Institut Claudius Regaud; Departement Oncologie Medicale, Toulouse, 31059, France|Centre Alexis Vautrin; Oncologie Medicale, Vandoeuvre-les-nancy, 54519, France|HELIOS Klinikum Berlin-Buch; Klinik für Gynäkologie und Geburtshilfe, Berlin, 13125, Germany|Campus Virchow-Klinikum Charité; Centrum 17; Klinik für Gynäkologie, Berlin, 13353, Germany|Evangelischen Krankenhauses Düsseldorf; Frauenklinik, Düsseldorf, 40217, Germany|Uni-Frauenklinik, Düsseldorf, 40225, Germany|Universitätsklinikum Erlangen; Frauenklinik, Erlangen, 91054, Germany|Universitätsklinikum Essen; Zentrum Für Frauenheilkunde, Essen, 45122, Germany|Klinikum Essen-Mitte Ev. Huyssens-Stiftung / Knappschafts GmbH; Klinik für Senologie / Brustzentrum, Essen, 45136, Germany|Klinik Johann Wolfgang von Goethe Uni; Klinik für Frauenheilkunde und Geburtshilfe, Frankfurt, 60596, Germany|Kath.Marienkrankenhaus gGmbH Frauenklinik, Hamburg, 22087, Germany|Gynaekologisch-Onkologische Schwerpunktpraxis Prof. Dr. med. Lueck, Dr. Schrader und Dr. Noeding, Hannover, 30177, Germany|Praxisgemeinschaft; Frauenärzte am Bahnhofsplatz, Hildesheim, 31134, Germany|Klinikum Kassel GmbH; Klinik für Frauenheilkunde und Geburtshilfe, Kassel, 34125, Germany|UNI-Klinikum Campus Kiel Klinik für Gynäkologie und Geburtshilfe, Kiel, 24105, Germany|HELIOS Klinikum Krefeld; Klinik für Frauenheilkunde und Geburtshilfe, Krefeld, 47805, Germany|Universitätsklinikum Schleswig-Holstein / Campus Lübeck; Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, 23538, Germany|Universitätsklinikum Mannheim; Frauenklinik, Mannheim, 68167, Germany|Klinikum der Universität München; Campus Großhadern; Klinik und Poliklinik für Frauenheilkunde, Muenchen, 81377, Germany|Klinikum Nord Frauenklinik, Nürnberg, 90419, Germany|Sana Klinikum Offenbach GmbH; Klinik für Gynäkologie & Geburtshilfe, Offenbach, 63069, Germany|Oncologianova GmbH, Recklinghausen, 45659, Germany|Universitätsfrauen- und Poliklinik am Klinikum Suedstadt, Rostock, 18059, Germany|Städtisches Klinikum Solingen; Klinik für Frauenheilkunde und Geburtshilfe, Solingen, 42653, Germany|Robert-Bosch-Krankenhaus; Interdisziplinäres Zentrum; Tumorzentrum, Stuttgart, 70376, Germany|Universitätsklinik Tübingen; Frauenklinik & Poliklinik, Tübingen, 72076, Germany|Universitätsklinikum Ulm Am Michelsberg; Frauenklinik, Ulm, 89075, Germany|Dr. Horst-Schmidt-Kliniken; Frauenheilkunde & Geburtshilfe, Wiesbaden, 65199, Germany|University Hospital of Alexandra, Athens, 11528, Greece|Irccs Centro Di Riferimento Oncologico (CRO); Dipartimento Di Oncologia Medica, Aviano, Friuli-Venezia Giulia, 33081, Italy|A.O. Universitaria S. Maria Della Misericordia Di Udine; Oncologia, Udine, Friuli-Venezia Giulia, 33100, Italy|AZIENDA POLICLINICO UMBERTO I; Ginecologia ed Ostetricia, Roma, Lazio, 00161, Italy|Istituto Regina Elena; Oncologia Medica A, Roma, Lazio, 00168, Italy|Ospedale S.G.Calibita Fatebenefratelli; Unità Operativa Oncologia, Roma, Lazio, 00186, Italy|Ospedali Riuniti; Divisione Ostetricia e Ginecologia, Bergamo, Lombardia, 24128, Italy|Az. Osp. Carlo Poma; Divisione Di Oncologia Medica, Mantova, Lombardia, 46100, Italy|Istituto Nazionale dei Tumori; Divisione Oncologia Chirurgica e Ginecologica, Milano, Lombardia, 20133, Italy|Meander Mc, Locatie Lichtenberg; Dept of Lung Diseases, Amersfoort, 3818 ES, Netherlands|Leyenburg Ziekenhuis; Internal Medecine, Den Haag, 2545 CH, Netherlands|Catharina ZKHS; Inwendige Geneeskunde Afd., Eindhoven, 5623 EJ, Netherlands|Martini Ziekenhuis; Dept of Internal Medicine, Groningen, 9728 NT, Netherlands|Stichting St. Antonius Ziekenhuis, Nieuwegein, 3430 EM, Netherlands|Universitair Medisch Centrum Utrecht; Inwendige Geneeskunde Afd., Utrecht, 3584 CX, Netherlands|The Norvegian Radium Hospital Montebello; Dept of Oncology, Oslo, 0379, Norway|St. Olavs Hospital; Kvinneklinikken, Trondheim, 7006, Norway|IPO de Lisboa; Servico de Oncologia Medica, Lisboa, 1099-023, Portugal|IPO do Porto; Servico de Oncologia Medica, Porto, 4200-072, Portugal|Corporacio Sanitaria Parc Tauli; Servicio de Oncologia, Sabadell, Barcelona, 8208, Spain|Hospital Universitario Marques de Valdecilla; Servicio de Oncologia, Santander, Cantabria, 39008, Spain|Hospital Universitario Reina Sofia; Servicio de Oncologia, Córdoba, Cordoba, 14004, Spain|Hospital Son Llatzer; Servicio de Oncologia, Palma de Mallorca, Islas Baleares, 07198, Spain|Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, 08035, Spain|Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia, Barcelona, 08041, Spain|Hospital de Terrassa; Servicio de Oncologia, Barcelona, 08227, Spain|Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Oncologia, Lerida, 25198, Spain|Hospital General Universitario Gregorio Marañon; Servicio de Oncologia, Madrid, 28007, Spain|Centro Oncologico MD Anderson Internacional; Servicio de Oncologia, Madrid, 28033, Spain|Centro Integral Oncologico Clara Campal (CIOCC); Dirección Médica, Madrid, 28050, Spain|Hospital General Universitario J.M Morales Meseguer; Servicio de Oncologia, Murcia, 30008, Spain|Instituto Valenciano Oncologia; Oncologia Medica, Valencia, 46009, Spain|Hospital Universitario la Fe; Servicio de Oncologia, Valencia, 46026, Spain|Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza, 50009, Spain|Uni Hospital Linkoeping; Dept. of Oncology, Linköping, 58185, Sweden|Norrlands Uni Hospital; Onkologi Avd., Umeå, 901 85, Sweden|Akademiska sjukhuset, Onkologkliniken, Uppsala, 751 85, Sweden|Örebro University Hospital; Department of Gynecologic Oncology, Örebro, 70185, Sweden|Adana Baskent University Hospital; Medical Oncology, Adana, 01120, Turkey|Ankara Baskent University Medicine Faculty; Gynaecology, Ankara, 06500, Turkey|Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology, Istanbul, 34300, Turkey|Anadolu Health Center; Medical Oncology, Kocaeli, 41400, Turkey",
